PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-4.08%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses growth above 20% signals concerning cost expansion. Seth Klarman would scrutinize unusual items.
21.99%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
21.99%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A growth above 10% signals heavy asset expansion. Seth Klarman would demand evidence of future payoff.
32.89%
EBITDA growth above 15% demonstrates exceptional operating performance. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
32.68%
Pre-tax income growth above 15% demonstrates exceptional profitability improvement. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Net income growth above 15% demonstrates exceptional bottom-line expansion. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS growth above 15% demonstrates exceptional shareholder value creation. Warren Buffett would verify sustainability.
32.51%
Diluted EPS growth above 15% demonstrates exceptional value creation despite potential dilution. Warren Buffett would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.